What is uMed?
uMed is a forward-thinking company dedicated to advancing life science research by creating a crucial link between patient experiences and empirical data. The organization provides a flexible, modular system of decentralized study services. These services encompass patient recruitment and the collection of vital data, all designed to accelerate the generation of more representative evidence. uMed's solutions are tailored for pharmaceutical teams, clinical trial professionals, and healthcare providers, aiming to streamline study operations and ensure access to diverse patient populations. A strong emphasis on data security and regulatory compliance is central to uMed's mission, fostering patient trust while enabling groundbreaking medical investigations.
How much funding has uMed raised?
uMed has raised a total of $12.4M across 1 funding round:
Other Financing Round
$12.4M
Other Financing Round (2023): $12.4M with participation from 11.2 Capital, Playfair Capital, Delin Ventures, and Albion Ventures
Key Investors in uMed
11.2 Capital
11.2 Capital is a venture capital firm specializing in emerging technologies, with a focus on AI, cybersecurity, and robotics, indicating a strategic interest in innovative tech solutions.
Playfair Capital
Playfair Capital is a London-based venture capital firm focused on pre-seed investments, particularly in the UK and Europe, suggesting a role in early-stage growth and strategic development for uMed.
Delin Ventures
Delin Ventures is an investor and company builder focused on life sciences and technology, aligning with uMed's mission to enhance life science research through innovative solutions.
What's next for uMed?
With the recent influx of major strategic investment, uMed is well-positioned to accelerate its growth trajectory. The company is likely to focus on expanding its service offerings, enhancing its technology platform, and broadening its market reach. Further development of its decentralized study services, particularly in patient recruitment and data collection, will be critical. Strategic partnerships and continued innovation in secure, compliant data handling will be key to solidifying its position in the competitive life science research landscape. This substantial backing signals a strong belief in uMed's model for generating faster, more representative evidence in medical research.
See full uMed company page
